Publications by authors named "Ju-Ying Wei"
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
J Hematol Oncol
October 2022
Article Synopsis
- - The study focused on treating high-risk acute promyelocytic leukemia (APL) using oral arsenic and all-trans retinoic acid (ATRA) without chemotherapy, aiming for effective outpatient care.
- - In a phase 2 clinical trial with 54 participants, the 2-year disease-free survival (DFS) rate was 94% and overall survival (OS) was 100%, with complete molecular remission achieved by all patients after consolidation.
- - Adverse events were mostly mild (grade 1-2), with only three cases of serious (grade 3) complications, indicating that the combination therapy was a safe and promising first-line treatment for high-risk APL.
Article Synopsis
- Exosomes derived from diffuse large B cell lymphoma (DLBCL) cells exhibit malignancy markers and play a crucial role in immune suppression, tumor growth, and angiogenesis, with distinct protein profiles compared to Burkitt lymphoma exosomes.
- The research explored various methods to analyze these exosomes and their interactions with immune and stromal cells, revealing that DLBCL exosomes can induce T cell apoptosis while promoting clonal expansion through dendritic cells.
- The findings indicate potential for developing new immunotherapies that target these tumor-derived exosomes to improve treatment outcomes for DLBCL patients.
[Therapeutic Efficacy of VICP+L-ASP/TKI on Adult Patients with B-ALL].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2016
Objective: To evaluate the therapeutic efficacy of VICP+L-ASP/TKI on adult patients with B-ALL and to explore the influence factors.
Methods: Forty-one adult B-ALL patients treated with VICP+L-ASP/TKI from August 2008 to June 2014 were following-up. The complete remission(CR) rate, toxicity, overall survival(OS) and event free survival(EFS) after induction treatment were analyzed, the therapeutic outcome of patients between different risk stratification subgroups was compared, the influence of standardized consolidatory and maintaining treatment as well as allogeneic hematopoietic stem cell transplantation(allo-HSCT) on survival time was analyzed.
The effect of time from diagnosis to treatment (TDT) on overall survival of patients with acute myeloid leukemia (AML) remains obscure. Furthermore, whether chemotherapy delay impacts overall survival (OS) of patients with a special molecular subtype has not been investigated. Here, we enrolled 364 cases of AML to assess the effect of TDT on OS by fractional polynomial regression in the context of clinical parameters and genes of FLT3ITD, NPM1, CEBPA, DNMT3a, and IDH1/2 mutations.
View Article and Find Full Text PDFDecitabine (DAC) is commonly used for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Previous studies have indicated DAC sequentially combined with idarubicin was an effective treatment for myeloid neoplasms. Therefore, a clinical study was conducted of the sequential combination of DAC followed by low-dose idarubicin/cytarabine in high-risk myeloid neoplasms.
View Article and Find Full Text PDFObjective: To assess the prevalence and clinical characteristics of isocitrate dehydrogenase 1 and 2 (IDH 1 and IDH2) gene mutations in myelodysplastic syndrome (MDS) patients.
Methods: Pretreatment bone marrow specimens were enriched for mononuclear cells in 108 adult patients with de novo MDS from January 2006 to August 2012. Genomic DNA was extracted from mononuclear cells.
Patients with hematologic disease are likely to be at increased risk for infection with influenza. We retrospectively analyzed 11 cases of patients with hematologic disease who were infected with pandemic H1N1 virus in our department, including their clinical manifestations, laboratory and imaging findings, outcomes of antiviral therapy, and factors associated with mortality. Notably, nine patients had lower respiratory tract disease.
View Article and Find Full Text PDFBortezomib in treatment of extramedullary plasmacytoma of the pancreas.
Hepatobiliary Pancreat Dis Int
June 2009
Background: Extramedullary pancreatic plasmacytoma treated with bortezomib is rarely reported.
Methods: We admitted a 53-year-old woman with an asymptomatic mass above the left clavicle for over three months, then an asymptomatic swelling of the pancreas was found. A biopsy on the mass and a fine needle aspiration of the pancreas were performed.